Items tagged as: prostate cancer

Earlier abiraterone shows survival benefit

Adding abiraterone (Zytiga) to standard hormone therapy at the start of treatment in men with advanced prostate cancer improves survival by 37%, according to trial results published in the New England Journal of Medicine (http://www.nejm.org/doi/10.1056/NEJMoa1702900).
In the study, part of the large STAMPEDE trial, 1900 patients …

More details...

Blood test for tailored prostate cancer treatment

A blood test could help identify which advanced prostate cancer patients are likely to fail on abiraterone (Zytiga) or enzalutamide (Xtandi), according to new research (Ann Oncol 2017;doi: 10.1093/annonc/mdx155).
The test, developed by scientists at The Institute of Cancer Research (ICR) and Royal Marsden Hospital, analyses …

More details...

Italian coffee cuts prostate cancer risk

Drinking more than three cups of Italian-style coffee a day could halve the risk of prostate cancer.
A study published in the International Journal of Cancer (doi: 10.1002/ijc.30720) measured coffee intake and assessed prostate cancer risk in nearly 4000 Italian men aged over 50.
Over an average …

More details...

TRoMbone calls for recruits

Researchers are recruiting patients for a pilot study looking at the potential benefits of radical prostatectomy plus extended pelvic lymphadectomy in addition to standard treatment in patients with prostate cancer and oligometastases to the bone.
There is some evidence that treating the primary tumour in men …

More details...

New prostate cancer aggressiveness test

Researchers at the University of East Anglia have developed a new categorisation for prostate cancer that could predict more accurately which ones are aggressive.
They analysed databases of gene activity in different prostate cancer samples and compared this to how the cancers responded to treatment. Using …

More details...

Work needed to fulfil PROMIS

Urgent action needs to be taken to enable men to benefit from the recent advance in prostate cancer diagnosis, according to Prostate Cancer UK (PCUK).
The charity was responding to the widely reported Prostate MRI Imaging Study (PROMIS) results showing improved diagnosis of prostate cancer with …

More details...

Laser-activated drug reduces prostate cancer progression

Laser-activated drug treatment of low-risk prostate cancer can reduce progression with few side-effects – according to a study published in the Lancet.
In a multi-centre European study of over 400 men with localised cancer (Gleason grade 3), half were given photodynamic therapy consisting of padeliporfin intravenously, …

More details...

High-dose testosterone looks positive in prostate cancer

Alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to abiraterone or enzalutamide, according to results presented recently in Munich.
Researchers at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics reported …

More details...

PSA test on Royal Colleges’ blacklist

PSA testing is included in a list of 40 treatments or interventions that bring ‘little or no benefit to patients’ drawn up by The Academy of Medical Royal Colleges. According to the Academy the list was compiled in a bid to reduce unnecessary, and sometimes …

More details...

Alcohol and prostate cancer linked

Alcohol may increase the risk of prostate cancer according to a meta-analysis published in BMC Cancer.
The study from Canadian and Australian researchers showed that drinking alcohol was linked to an increased risk of between 8% and 23%. Heavy drinkers appeared to be at higher risk.
A …

More details...

Web design and marketing agency Leamington Spa